Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeoVax Labs, Inc. filings document a clinical-stage biotechnology issuer developing multi-antigenic vaccines and immunotherapies for infectious diseases and cancer. The company’s regulatory disclosures cover operating and financial results, research and development activity, clinical and regulatory updates for programs such as GEO-MVA, GEO-CM04S1 and Gedeptin, and risks associated with development-stage biotechnology operations.
Its SEC record also includes proxy materials on governance, executive compensation and equity awards; registration statements and 8-K reports covering common stock, warrants, registered offerings and other capital-structure matters; and material-event disclosures related to agreements, reporting status and shareholder voting matters.
GeoVax Labs, Inc. director John N. Spencer Jr reported receiving a grant of stock options covering 6,000 shares of GeoVax common stock. The options have an exercise price of $1.18 per share, become exercisable on June 17, 2027, and expire on June 17, 2036. Following this grant, he holds 6,000 stock options directly.
GeoVax Labs, Inc. director Morgan Jayne received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $1.18 per share, become exercisable on June 17, 2027, and are scheduled to expire on June 17, 2036. This is a compensation-related award reported as an acquisition of derivative securities, not an open-market purchase or sale of common stock.
GeoVax Labs, Inc. director Robert T. McNally received a grant of stock options covering 6,000 shares of common stock. The options have a $1.18 per-share exercise price, become exercisable on June 17, 2027, and expire on June 17, 2036. Following this compensation-related award, his directly held derivative position from this grant totals 6,000 options, and the filing shows no open-market buying or selling activity.
GeoVax Labs director Nicole Lemerond received a grant of 6,000 stock options for GeoVax Labs, Inc. common stock. These options were awarded at an exercise price of $1.18 per share and are scheduled to expire on June 17, 2036. Following this grant, she holds 6,000 derivative securities directly, reflecting a routine equity compensation award rather than an open-market purchase or sale.
GeoVax Labs director Dean G. Kollintzas received a grant of 6,000 stock options on common stock. The options have a conversion or exercise price of $1.18 per share and relate to 6,000 underlying common shares. They expire on June 17, 2036, and his derivative holdings after this award total 6,000 options held directly.
GeoVax Labs, Inc. director Randal D. Chase received a grant of stock options covering 6,000 shares of common stock. The options carry an exercise price of $1.18 per share, become exercisable on June 17, 2027, and expire on June 17, 2036. Following this award, he holds 6,000 options directly.
GeoVax Labs, Inc. granted stock options to a senior executive. VP of Business Development John W. Sharkey received an award of 17,600 stock options for common stock on June 17, 2026 at an exercise price of $1.18 per share.
The options vest in three equal annual installments on the first three anniversaries of the grant date and expire on June 17, 2036. This is a compensation-related grant, not an open-market purchase or sale, and leaves Sharkey holding 17,600 options directly after the transaction.
GeoVax Labs CFO Mark Reynolds received a grant of stock options covering 17,600 shares of common stock. The options have an exercise price of $1.18 per share and expire on June 17, 2036. They become exercisable in three equal annual installments on the first three anniversaries of the grant date.
GeoVax Labs, Inc. reported that Chief Scientific Officer Mark J. Newman received a grant of stock options covering 17,600 shares of common stock. The options have an exercise price of $1.18 per share, vest in three equal annual installments starting on the first anniversary of the grant, and expire on June 17, 2036.
GeoVax Labs, Inc. reported that Chief Medical Officer Kelly T. McKee Jr. received a grant of stock options covering 17,600 shares of common stock. The options have an exercise price of $1.18 per share, vest in three equal annual installments starting on the first anniversary of the grant date, and expire on June 17, 2036. Following this award, McKee holds 17,600 stock options directly.